NEW YORK – Delic Labs has entered into a comarketing partnership with GT Research to provide detailed genomic analyses related to commercially interesting traits found in cannabis and psychedelic mushrooms to Canadian producers, its parent company Delic said on Tuesday.
Services provided under the agreement include sample preparation, DNA extraction, whole-genome sequencing, and computational analyses.
Delic Labs, a subsidiary of Delic, focuses on identifying scalable legal psychedelic medicine opportunities. As one of Canada's few licensed psilocybin labs, it applies chemical analytics, metabolomic identification, and process optimization to the psychedelics industry.
GTR performs gene profiling and trait optimization services related to the production of cannabis and psychedelics.
"As the cannabis and psychedelic sectors grow, interest in genomic analysis of the underlying organisms is increasing. GTR is excited to offer its cutting-edge suite of capabilities in partnership with Delic, a pioneer in this space," Sam Proctor, cofounder and CEO of GTR, said in a statement.
"Delic is committed to researching and identifying the safest, highest quality psychedelic compounds for commercial use," said Matt Stang, cofounder and CEO of Delic.